ATB200-03: A PHASE 3 DOUBLE-BLIND RANDOMIZED STUDY TO ASSESS THE EFFICACY AND SAFETY OFINTRAVENOUS ATB200 CO-ADMINISTERED WITH ORAL AT2221 IN ADULT SUBJECTS WITH LATE ONSETPOMPE DISEASE COMPARED WITH ALGLUCOSIDASE ALFA/PLACEBO

Medicine & Life Sciences

1. human GAA protein 100%
2. Carbon Monoxide 58%
3. Double-Blind Method 56%
4. Glycogen Storage Disease Type II 41%
5. Placebos 39%
6. Late Onset Disorders 38%
7. Safety 33%